Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Filip De Keyser

Showing results (11-20 of 104) with videos related to

Pageof 11
Sort By:
Current Opinion in Rheumatology|July 16, 2002
Immune linkages between inflammatory bowel disease and spondyloarthropathiesDominique Baeten, Filip De Keyser, Herman Mielants, et al.
Current Rheumatology Reports|May 28, 2005
Gut inflammation in the spondyloarthropathiesHerman Mielants, Filip De Keyser, Dominique Baeten, et al.
Clinical and Experimental Rheumatology|March 24, 2015
Factors influencing the occupational trajectory of patients with systemic sclerosis: a qualitative studySaskia Decuman, Vanessa Smith, Maria Grypdonck, et al.
The Journal of Rheumatology|June 3, 2014
Ten-year followup of infliximab therapy in rheumatoid arthritis patients with severe, longstanding refractory disease: a cohort studyFilip De Keyser, Joris De Kock, Hermine Leroi, et al.
Clinical Chemistry|November 26, 2002
Detection of specific antinuclear reactivities in patients with negative anti-nuclear antibody immunofluorescence screening testsIlse E A Hoffman, Isabelle Peene, Eric M Veys, et al.
The Journal of Rheumatology|August 17, 2014
Longterm followup of rituximab therapy in patients with rheumatoid arthritis: results from the Belgian MabThera in Rheumatoid Arthritis registryFilip De Keyser, Ilse Hoffman, Patrick Durez, et al.
Arthritis Research & Therapy|May 19, 2005
Tumor necrosis factor-alpha blockade in ankylosing spondylitis: a potent but expensive anti-inflammatory treatment or true disease modification?Filip Van den Bosch, Filip De Keyser, Herman Mielants, et al.
Clinical and Experimental Rheumatology|July 8, 2016
Disease activity indices in systemic sclerosis: a systematic literature reviewKarin Melsens, Filip De Keyser, Saskia Decuman, et al.
Rheumatology (Oxford, England)|October 6, 2011
Work participation and work transition in patients with systemic sclerosis: a cross-sectional studySaskia Decuman, Vanessa Smith, Sofie Verhaeghe, et al.
Arthritis Research & Therapy|March 2, 2011
Histopathological cutaneous alterations in systemic sclerosis: a clinicopathological studyJens T Van Praet, Vanessa Smith, Marc Haspeslagh, et al.
Pageof 11

Showing results (11-20 of 104) with videos related to

Sort By:
Pageof 11
Current Opinion in Rheumatology|July 16, 2002
Immune linkages between inflammatory bowel disease and spondyloarthropathiesDominique Baeten, Filip De Keyser, Herman Mielants, et al.
Current Rheumatology Reports|May 28, 2005
Gut inflammation in the spondyloarthropathiesHerman Mielants, Filip De Keyser, Dominique Baeten, et al.
Clinical and Experimental Rheumatology|March 24, 2015
Factors influencing the occupational trajectory of patients with systemic sclerosis: a qualitative studySaskia Decuman, Vanessa Smith, Maria Grypdonck, et al.
The Journal of Rheumatology|June 3, 2014
Ten-year followup of infliximab therapy in rheumatoid arthritis patients with severe, longstanding refractory disease: a cohort studyFilip De Keyser, Joris De Kock, Hermine Leroi, et al.
Clinical Chemistry|November 26, 2002
Detection of specific antinuclear reactivities in patients with negative anti-nuclear antibody immunofluorescence screening testsIlse E A Hoffman, Isabelle Peene, Eric M Veys, et al.
The Journal of Rheumatology|August 17, 2014
Longterm followup of rituximab therapy in patients with rheumatoid arthritis: results from the Belgian MabThera in Rheumatoid Arthritis registryFilip De Keyser, Ilse Hoffman, Patrick Durez, et al.
Arthritis Research & Therapy|May 19, 2005
Tumor necrosis factor-alpha blockade in ankylosing spondylitis: a potent but expensive anti-inflammatory treatment or true disease modification?Filip Van den Bosch, Filip De Keyser, Herman Mielants, et al.
Clinical and Experimental Rheumatology|July 8, 2016
Disease activity indices in systemic sclerosis: a systematic literature reviewKarin Melsens, Filip De Keyser, Saskia Decuman, et al.
Rheumatology (Oxford, England)|October 6, 2011
Work participation and work transition in patients with systemic sclerosis: a cross-sectional studySaskia Decuman, Vanessa Smith, Sofie Verhaeghe, et al.
Arthritis Research & Therapy|March 2, 2011
Histopathological cutaneous alterations in systemic sclerosis: a clinicopathological studyJens T Van Praet, Vanessa Smith, Marc Haspeslagh, et al.
Pageof 11